Michael Chiorean

Real-world clinical outcomes and healthcare costs in patients with Crohn’s disease treated with vedolizumab versus ustekinumab in the United States

H. Romdhani, N. Candela, R. Bungay, 2024, Current medical research and opinion.

Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system

J. Hadlock, S. Molani, Wanessa F Matos, 2024, The Lancet. Digital health.

Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US healthcare system

J. Hadlock, S. Molani, Wanessa F Matos, 2023, medRxiv.